Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma

NCT07093554 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

31

Enrollment

OTHER

Sponsor class

Conditions

Relapse Multiple Myeloma
Refractory Multiple Myeloma

Interventions

DRUG: Talquetamab
DRUG: Ciltacabtagene Autoleucel

Sponsor

Medical College of Wisconsin